Abstract #2755

Development of USPIO-DM1-5D3-CF750: An image-guided targeted drug delivery system for prostate cancer therapy

Sudath Hapuarachchige^1,2, Ge Si^1,3, Catherine Foss¹, Cyril Barinka⁴, and Dmitri Artemov^1,2

¹Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD, United States, ²Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States, ³Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD, United States, ⁴Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic

Synopsis

Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancers (PC) compared to normal tissues. Hence, PSMA can be used as a diagnostic biomarker and biological target to deliver drugs in PC therapy. In this study, we have conjugated ultra-small superparamagnetic iron oxide nanoparticles with mertansine (DM1), a chemotherapeutic drug, novel anti-PSMA 5D3 antibody, and NIR CF-750 fluorophore. This multimodality image-guided drug delivery system was evaluated in PC mouse models using in vivo fluorescent imaging and MRI at 9.4T. Promising results encourage further development of targeted image-guided drug delivery platforms for PC therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.